Oxford Nanopore Technologies PLC (ONTTF)
1.365
-0.08
(-5.86%)
USD |
OTCM |
May 17, 14:37
Price Chart
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.177B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | -54.50% |
Valuation | |
PE Ratio | -- |
PE Ratio (Forward) | Upgrade |
PS Ratio | 5.381 |
Price to Book Value | 1.436 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | -- |
Profile
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
URL | https://www.nanoporetech.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Small Cap/Blend |
Next Earnings Release | Sep. 06, 2024 (est.) |
Last Earnings Release | Mar. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ratings
Profile
Oxford Nanopore Technologies PLC makes a novel generation of DNA/RNA sequencing technology that provides rich data and is fast, accessible, and easy to use. The company is predominantly involved in researching, developing, manufacturing, and commercializing a nanopore-based sequencing platform that allows the real-time analysis of deoxyribonucleic acid (DNA) or ribonucleic acid (RNA). This enables its customers to perform scientific/biomedical research in a range of areas, including human genetics, cancer research, outbreak surveillance, environmental analysis, pathogens/antimicrobial resistance, microbiome analysis, and crop science. The company's reportable segments are; Life Science Research Tools which generates key revenue, and COVID Testing. |
URL | https://www.nanoporetech.com |
Investor Relations URL | N/A |
HQ State/Province | N/A |
Sector | Health Care |
Industry | Life Sciences Tools & Services |
Equity Style | Small Cap/Blend |
Next Earnings Release | Sep. 06, 2024 (est.) |
Last Earnings Release | Mar. 06, 2024 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |